Key Points Early cancer detection is highly beneficial to sufferers, and Grail's Galleri test offers a solution. The company is the leader in the race for FDA approval, but it could benefit from being part of a larger company. Commercial sales are growing, and cash burn reducing, while the company has ample cash resources. 10 stocks we like better than Grail › Grail (NASDAQ: GRAL) is a leader in the multi-cancer early detection market (MCED), and its stock rose 20.1% in November, according to data ...